Duchenne Muscular Dystrophy

Latest News

The primary outcome measure in the ambulatory cohort in the study was mean change from baseline to week 52 in the TTR from floor, and no significant differences were seen between the treatment and control groups. | Image credit: OlegKachura - stock.adobe.com
TAS-205 Misses Primary End Point in Phase 3 DMD Trial

July 11th 2025

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

While accommodations can improve quality of life for patients with DMD and foster independence, the costs of home and ve modifications fall mostly on the families of patients. | Image credit: Nadzeya - stock.adobe.com
Accommodations as DMD Progresses Incur Substantial Household Costs

July 10th 2025

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com
AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

June 30th 2025

An analysis of outcomes from part 2 of the EMBARK trial included 14 patients who had received a placebo in part 1 of the study and were aged 8 to 9 years at crossover. | Image Credit: RFBSIP - stock.adobe.com
DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

June 13th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo